Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 0.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 751,804 shares of the company’s stock after selling 3,887 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.19% of Moderna worth $21,314,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new stake in Moderna in the fourth quarter valued at about $41,000. Itau Unibanco Holding S.A. lifted its position in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after acquiring an additional 343 shares during the period. Vega Investment Solutions acquired a new stake in shares of Moderna during the 4th quarter valued at approximately $45,000. Sentry Investment Management LLC acquired a new stake in shares of Moderna during the 1st quarter valued at approximately $31,000. Finally, CBIZ Investment Advisory Services LLC lifted its position in shares of Moderna by 4,400.0% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 1,125 shares of the company’s stock valued at $47,000 after acquiring an additional 1,100 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 0.6%

Shares of NASDAQ MRNA opened at $30.47 on Friday. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $129.39. The firm has a fifty day moving average of $26.65 and a 200-day moving average of $31.52. The stock has a market capitalization of $11.78 billion, a PE ratio of -3.49 and a beta of 1.84.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. During the same period in the previous year, the company earned ($3.07) EPS. The business’s quarterly revenue was down 35.3% compared to the same quarter last year. Equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MRNA. Evercore ISI reduced their price target on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research report on Friday, May 2nd. Morgan Stanley reduced their price target on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Barclays dropped their price objective on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating for the company in a research note on Thursday, May 22nd. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $46.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.